OP-069 Effect of bosentan on lung histopathology in a chronic asthma model created in balb/c mice

AimAsthma is a chronic disease which is characterized by bronchial hyperactivity and progresses with the bronchospasm following chronic inflammation of the bronchial system. The most powerful anti-inflammatory drugs known to treat asthma are steroids. However, due to the side effects of steroids, the prospect of investigating alternative therapies is increasing. The aim of our study is to evaluate the effects of bosentan, an anti-inflammatory, antiproliferative, non-selective endothelin A and endothelin B receptor antagonist, on lung histopathology in chronic asthma-modeled BALB/c mice.Material and MethodThe study was performed on a total of 35 BALB/c mice. The mice were divided into four groups as control group, placebo group, dexamethasone group and bosentan group. IL-4, IL-5 and Thymic Stromal Lymphopoietin (TSLP) levels in serum and lung tissues, mast and goblet cells and epithelial and smooth muscle thicknesses in tissue sections were evaluated in all groups after the formation of asthma model (figure 1). Our study was approved by the Pamukkale University Experimental Animals Ethics Commission (2016TIPF011).ResultsThere was no found statistically difference between the groups for the serum IL-4, IL-5 and TSLP levels (p>0.05). IL-5 levels in the lung tissues were found as 5.06±1.38 pg/ml and 3.43±0.55 pg/ml in the asthma and bosentan groups respectively (p